Latest Blogs, Articles, and More
The Food and Drug Administration has approved its first biosimilar, Zarxio (filgrastim-sndz), for all five of its counterpart Neupogen's authorized indications.
Treating patients with triple-negative breast cancer (TNBC) remains a challenge because these tumors do not rely on hormone receptors or HER2 amplification for tumor growth.
Results of a new study may help more lung cancer patients be eligible to participate in clinical trials.Researchers found that previously having cancer does not impact clinical outcomes in lung cancer patients.
Living in denial is sometimes not such a bad idea, especially when it comes to cancer.
The Food and Drug Administration has approved the anti–PD-1 agent Opdivo (nivolumab) for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). The approval comes three months ahead of the FDA’s scheduled decision date.